BMJ  2005;330:644-648 (19 March), doi:10.1136/bmj.330.7492.644

Clinical review

Monitoring in chronic disease: a rational approach

Paul Glasziou, professor1, Les Irwig, professor2, David Mant, professor1

1 University of Oxford, Department of Primary Health Care, Oxford OX3 7LF UK, 2 Screening and Test Evaluation Program, School of Public Health, University of Sydney, Camperdown, NSW 2006, Australia

Correspondence to: P Glasziou paul.glasziou@dphpc.ox.ac.uk

The first 150 words of the full text of this article appear below.

Introduction

"Know which abnormality you are going to follow during treatment. Pick something you can measure."

Meador C. A Little Book of Doctors' Rules.

Lyons: IARC Press, 1999.

The ritual of routine visits for most chronic diseases usually includes monitoring to check on the progress or regress of the disease and the development of complications. Such checks require that we choose what to monitor, when to monitor, and how to adjust treatment. Poor choices in each can lead to poor control, poor use of time, and dangerous adjustments to treatment. For example, an audit of serum digoxin monitoring in a UK teaching hospital more than 20 years ago showed that the logic behind more than 80% of the tests requested could not be established, the timing of tests reflected poor understanding of the clinical pharmacokinetics, and about one result in four was followed by an inappropriate clinical decision.1 Improvements are . . . [Full text of this article]

Should we monitor at all?

The phases of monitoring

Pretreatment monitoring
Initial titration: response, control, and safety
Monitoring during treatment
Adjustment to re-establish control
Cessation of treatment

Monitoring strategy

Which measurement?
Choosing the monitoring interval
Who should monitor?

Discussion


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Articles

Use of randomised trials to decide when to monitor response to new treatment
Katy J L Bell, Les Irwig, Jonathan C Craig, and Petra Macaskill
BMJ 2008 336: 361-365. [Extract] [Full Text] [PDF]

Charcot would have approved
Fiona Godlee
BMJ 2005 330: 0. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Bell, K. J L, Irwig, L., Craig, J. C, Macaskill, P. (2008). Use of randomised trials to decide when to monitor response to new treatment. BMJ 336: 361-365 [Full text]  
  • Tennant, R., Mohammed, M. A., Coleman, J. J., Martin, U. (2007). Monitoring patients using control charts: a systematic review. Int J Qual Health Care 19: 187-194 [Abstract] [Full text]  
  • van den Bemt, L., Schermer, T., van Weel, C. (2007). Rational monitoring of COPD: where do current clinical guidelines stand?. Eur Respir J 29: 1078-1081 [Full text]  
  • Kuperman, G. J., Bobb, A., Payne, T. H., Avery, A. J., Gandhi, T. K., Burns, G., Classen, D. C., Bates, D. W. (2007). Medication-related Clinical Decision Support in Computerized Provider Order Entry Systems: A Review. J. Am. Med. Inform. Assoc. 14: 29-40 [Abstract] [Full text]  
  • Groves, T., Wagner, E. H (2005). High quality care for people with chronic diseases. BMJ 330: 609-610 [Full text]  



Student BMJ

Intimate examinations

Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.

www.student.bmj.com

Listen to the latest BMJ Interview